These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37805968)

  • 21. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J; Gatault P; Sautenet B; Gaudy-Graffin C; Beby-Defaux A; Thierry A; Essig M; Halimi JM; Munteanu E; Alain S; Buchler M
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R; Serluco A; Nance G; George R; Rodriguez DS; Deshpande S; Mao C; Garro R; Yildirim I
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation.
    Páez-Vega A; Cantisán S; Agüera ML; Suñer M; Facundo C; Yuste JR; Fernández-Ruiz M; Montejo M; Redondo-Pachón D; López-Oliva MO; Fernández-Rodríguez A; Fariñas MC; Hernández D; Len O; Muñoz P; Valle-Arroyo J; Rodelo-Haad C; Cordero E; Torre-Cisneros J
    J Infect Dis; 2021 Apr; 223(7):1205-1213. PubMed ID: 32779713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia.
    Pizzo H; Shin B; Garrison J; Huang E; Malekzadeh M; Jordan SC; Puliyanda D; Toyoda M
    Pediatr Transplant; 2021 Dec; 25(8):e14119. PubMed ID: 34390094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
    Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
    Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A split strategy to prevent cytomegalovirus after kidney transplantation using prophylaxis in serological high-risk patients and a pre-emptive strategy in intermediate-risk patients: Combining the best of two options?
    Hellemans R; Wijtvliet V; Bergs K; Philipse E; Vleut R; Massart A; Couttenye MM; Matheeussen V; Abramowicz D
    Transpl Infect Dis; 2021 Apr; 23(2):e13467. PubMed ID: 32935909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
    Tarasewicz A; Dębska-Ślizień A; Rutkowski B
    Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.
    Snyder LD; Medinas R; Chan C; Sparks S; Davis WA; Palmer SM; Weinhold KJ
    Am J Transplant; 2011 Mar; 11(3):553-60. PubMed ID: 21219584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
    Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
    Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of intracellular cytokine staining versus an ELISA-based assay to assess CMV-specific cell-mediated immunity in high-risk kidney transplant recipients.
    Fernández-Ruiz M; Redondo N; Parra P; Ruiz-Merlo T; Rodríguez-Goncer I; Polanco N; González E; López-Medrano F; San Juan R; Navarro D; Andrés A; Aguado JM
    J Med Virol; 2023 Apr; 95(4):e28733. PubMed ID: 37185851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J; Phonphok K; Spanuchart I; Duong T; Sievers TM; Lum E; Reed EF; Bunnapradist S
    Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Lee SM; Kim YJ; Yoo KH; Sung KW; Koo HH; Kang ES
    Ann Lab Med; 2017 May; 37(3):277-281. PubMed ID: 28224776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
    Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
    Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
    Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
    J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.
    Räihä J; Ortiz F; Mannonen L; Loginov R; Lempinen M; Lautenschlager I; Helanterä I
    Transpl Infect Dis; 2021 Aug; 23(4):e13577. PubMed ID: 33527660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.